About Keratin, type I cytoskeletal 20
Keratin, type I cytoskeletal 20 (KRT20) is a protein
from Homo sapiens identified by UniProt accession
P35900, 424 residues long.
MolForge cross-references it against 0 known binders and
256 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 20 |
| UniProt accession | P35900 |
| Gene | KRT20 |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (256)
Diseases linked to this target (Open Targets).
- pancreatic adenocarcinoma · score 0.19
- glioblastoma multiforme · score 0.19
- breast adenocarcinoma · score 0.18
- low grade glioma · score 0.11
- neoplasm · score 0.10
- Barrett's esophagus · score 0.09
- head and neck squamous cell carcinoma · score 0.07
- colorectal carcinoma · score 0.07
- Merkel cell skin cancer · score 0.06
- esophageal adenocarcinoma · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35900-F1 | alphafold | PREDICTED | 79.24 | — |
Amino-acid sequence (424 residues)
MDFSRRSFHR SLSSSLQAPV VSTVGMQRLG TTPSVYGGAG GRGIRISNSR HTVNYGSDLT GGGDLFVGNE KMAMQNLNDR LASYLEKVRT LEQSNSKLEV QIKQWYETNA PRAGRDYSAY YRQIEELRSQ IKDAQLQNAR CVLQIDNAKL AAEDFRLKYE TERGIRLTVE ADLQGLNKVF DDLTLHKTDL EIQIEELNKD LALLKKEHQE EVDGLHKHLG NTVNVEVDAA PGLNLGVIMN EMRQKYEVMA QKNLQEAKEQ FERQTAVLQQ QVTVNTEELK GTEVQLTELR RTSQSLEIEL QSHLSMKESL EHTLEETKAR YSSQLANLQS LLSSLEAQLM QIRSNMERQN NEYHILLDIK TRLEQEIATY RRLLEGEDVK TTEYQLSTLE ERDIKKTRKI KTVVQEVVDG KVVSSEVKEV EENI
Explore Keratin, type I cytoskeletal 20 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets